GLIDE Score Emerges as a Robust Predictor of Success in Direct Transcatheter Tricuspid Valve Annuloplasty

Introduction: The Evolution of Tricuspid Intervention

The tricuspid valve, historically referred to as the forgotten valve, has moved to the forefront of structural heart intervention. Severe tricuspid regurgitation (TR) is associated with significant morbidity and mortality, yet surgical intervention remains high-risk for many patients due to comorbidities. Transcatheter therapies have emerged as a viable alternative, primarily categorized into transcatheter edge-to-edge repair (TEER) and transcatheter tricuspid valve annuloplasty (TTVA). While both aim to reduce TR, their mechanisms differ: TEER focuses on leaflet coaptation, whereas TTVA addresses annular dilatation. Identifying the right patients for these procedures is critical for procedural success and long-term outcomes. The GLIDE score, initially developed to predict success in TEER, has now been evaluated for its utility in TTVA, offering clinicians a standardized tool for preprocedural planning.

Highlighting Key Study Insights